SCHEMBL6098463

SCHEMBL6098463

[CH2]Cc1ccc(-n2nc(C)c(-c3cccc(F)c3)c2C)cc1

nearest known ligand 0.80

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.58
CYP2D6 P10635 1/20 0.43
AR P10275 3/20 0.41
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TAAR1 Q96RJ0 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SMO Q99835 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097637 0.88 CYP1A2 (0.59) CYP1A2CYP2D6ARKDM4EALDH1A1
SCHEMBL6097998 0.87 CYP1A2 (0.51) CYP1A2CYP2D6HTR1AHTR7KDM4E
SCHEMBL6096209 0.85 CYP1A2 (0.49) CYP1A2CYP2D6HTR1AHTR7KDM4E
SCHEMBL6099399 0.84 CYP1A2 (0.49) CYP1A2HTR1AHTR7ALDH1A1MAPT
SCHEMBL6096730 0.84 CYP1A2 (0.76) CYP1A2CYP2D6ARNPC1RAB9A
SCHEMBL6097575 0.84 CYP1A2 (0.56) CYP1A2KDM4EALDH1A1MAPTNPSR1
SCHEMBL6095984 0.84 CYP1A2 (0.48) CYP1A2KDM4EALDH1A1MAPTNPSR1
SCHEMBL6097500 0.80 CYP1A2 (0.49) CYP1A2CYP2D6ARKDM4EALDH1A1
SCHEMBL6095453 0.79 CYP1A2 (0.59) CYP1A2CYP2D6ARKDM4EALDH1A1
SCHEMBL6097652 0.79 CYP1A2 (0.50) CYP1A2CYP2D6ARALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001917-B2 Pyrazole compounds as anti-inflammatory and analgesic agents WARNER LAMBERT COMPANY LLC (US) 2006-02-21 US disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR CYP1A2 670/4885CYP2D6 801/4885AR 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.